Weaknesses In Gilead's Remdesivir Trial Designs Unlikely to Impact Approval Prospects In US

 
• By Sarah Karlin-Smith
Gilead sign at headquarters in Silicon Valley. Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs - Foster City, California, USA - 2020
Gilead said speed and a desire to test varying dosing regimens influenced their trial design decisions. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards